Feed excerpt — reported by STAT News
As telehealth platforms market GLP-1s for addiction, experts say that's getting ahead of evidence, and it could fragment care and expose patients to unknown risks.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →